ArticleDiscover oncology2025

Utilizing multi-omics analysis, a new signature has been identified and validated for predicting prognosis and response to immunotherapy in lung squamous cell carcinoma, which is based on tumor mutation burden.

Dongguang Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.